在手术去神经支配的小鼠模型中测试感觉神经功能

Executive Industry Relevance

Establishing causal relationships between sensory nerve activity and disease phenotypes is critical for target validation in dermatology and neuroscience drug discovery. This denervation model enables mechanistic de-risking by isolating nerve-dependent pathways, supporting predictive confidence in early target selection. The approach provides a disease-relevant system for evaluating therapeutic hypotheses prior to compound screening.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by testing nerve requirement in skin disease models.
• Operational Value: Provides a controlled system to clarify pathway involvement of sensory nerves.
• Strategic Value: Supports target de-risking through functional validation of nerve-dependent mechanisms.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems with denervated and innervated controls for compound testing.
• Operational Value: Enables standardized, reproducible mechanical stimulation assays to quantify nerve-dependent responses.
• Strategic Value: Facilitates reliable compound evaluation by distinguishing nerve-mediated from non-specific effects.

Translational & Preclinical Research

• Scientific Value: Aligns with disease-relevant systems by modeling denervation in cutaneous inflammation or fibrosis.
• Operational Value: Supports translational biomarker assessment through correlating nerve loss with phenotypic outcomes.
• Strategic Value: Informs risk-adjusted advancement decisions by validating target engagement in vivo.

Pipeline & Workflow Integration

The model integrates into discovery biology for hypothesis testing, enables assay development for screening readiness, and supports translational research through phenotypic continuity.

• Discovery Biology: Tests whether sensory nerves are required for disease phenotypes, clarifying mechanistic pathways.
• Screening: Generates quantitative, reproducible readouts via mechanical stimulation to assess compound effects in denervated vs. control tissue.
• Analytics: Provides binary or graded response measurements (e.g., shuddering, head turn) to compare conditions and support go/no-go decisions.
• Translational Research: Connects to preclinical validation by modeling stable denervation weeks post-surgery, mirroring chronic nerve loss in disease.
• Enterprise Reuse: Establishes a reusable surgical platform for multiple studies on nerve-skin interactions in dermatology, pain, and immunology.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by confirming nerve dependence through loss-of-function.
• Operational Value: Delivers standardized, reproducible denervation with internal contralateral controls.
• Strategic Value: Improves go/no-go decisions by validating target relevance before compound investment.
• Portfolio Impact: Enables risk-based prioritization of targets with demonstrated nerve-dependent pathophysiology.

Implementation Considerations

• Requires expertise in microsurgery and nerve identification under dissection microscopy.
• Dependent on sterile instruments, fine forceps, and saline-moistened tissue handling to prevent vascular damage.
• Necessitates standardized post-operative recovery and timed denervation validation (e.g., weeks post-surgery).
• Involves adaptation considerations for different dorsal anatomical zones (T3-T12) and skin flap integrity.
• Limited by technical nerve removal completeness; incomplete denervation may confound response interpretation.

Biopharma FAQs